The Optimal Activity of Radioactive Iodine for Remnant Ablation in Low/Intermediate Risk Differentiated Thyroid Carcinoma: A Continuous Controversy and Meta-Analysis-Reference-Cited by-同舟云学术

The Optimal Activity of Radioactive Iodine for Remnant Ablation in Low/Intermediate Risk Differentiated Thyroid Carcinoma: A Continuous Controversy and Meta-Analysis

Published:2021-01-27 Issue: Volume: Page:
ISSN:2168-8184
Container-title:Cureus
language:en
Short-container-title:

Author:

Mirghani Hyder,Altidlawi Mohammed I,Altedlawi Albalawi Ibrahim A

Publisher

Cureus, Inc.

Subject

Aerospace Engineering

Reference24 articles.

1. Radioactive iodine therapy for differentiated thyroid cancer: lessons from confronting controversial literature on risks for secondary malignancy;Tulchinsky M;J Nucl Med,2018

2. Quality of life in thyroid cancer is similar to that of other cancers with worse survival;Applewhite MK;World J Surg,2016

3. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer;Haugen BR;Thyroid,2016

4. Different radioiodine dose for remnant thyroid ablation in patients with differentiated thyroid cancer. A meta-analysis;Song X;Clin Nucl Med,2015

5. Low versus high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a meta-analysis of randomized controlled trials;Du P;Endocrine,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radioactive iodine effects of ovarian reserve: A systematic review and meta-analysis;2024-06-14

2. Early Dynamic Risk Stratification Decreases Rate of Ablative and Adjuvant Radioiodine Use in ATA Low and Intermediate Risk Papillary Thyroid Cancer Patients;SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital;2023

3. Comparing High and Low-Dose Radio-Iodine Therapy in Thyroid Remnant Ablation Among Intermediate and Low-Risk Papillary Thyroid Carcinoma Patients—Single Centre Experience;Dose-Response;2021-10